Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
9 Tips for Avoiding Tax Season Cyber Scams 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
AstraZeneca plc, a British-Swedish pharmaceutical and biotechnology company, is reportedly withdrawing its COVID-19 vaccine worldwide. The company made the decision months after admitting in court there is a rare side effect.
But then again, according to Channel News Asia, AstraZeneca did not say this was the reason for the pullout of the vaccines. Rather, the company said it was due to “commercial reasons.”
Taking Back the COVID-19 Vaccines Years After Release
AstraZeneca said on Tuesday, May 7, the withdrawal of its vaccines around the world is already underway. It stressed that this is due to a "surplus of available updated vaccines" since the pandemic.
Moreover, the pharmaceutical and biotech firm announced it would also retract the vaccine Vaxzevria's marketing authorizations in Europe. AstraZeneca added that it is no longer producing its COVID-19 vaccine, so supply to the market has also stopped.
“As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company’s spokesman said in a statement. “This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.”
Reported Side Effects of Vaxzevria
AstraZeneca reportedly admitted in court documents that the vaccine has side effects like low platelet counts and blood clots. British newspapers stated that based on legal documents, the company's vaccine may cause TTS, but in very rare cases. World Health Organization (WHO), said this condition called Thrombosis with Thrombocytopenia Syndrome is a serious and life-threatening negative effect.
“It is admitted that the AZ vaccine can, in very rare cases, cause TTS,” AstraZeneca said in court documents in February. “The causal mechanism is not known.”
UK’s The Independent reported that AstraZeneca’s admission came after it was sued in the U.K. The class action lawsuits alleged that the company’s vaccine caused deaths and severe injuries, and claimants are seeking damages up to £100 million for around 50 supposed victims.
Photo by: Mufid Majnun/Unsplash
